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TO THE EDITOR
Although the incidence of melanoma is
still rising in many countries, the exact
molecular pathogenesis for this tumor is
unknown. Consequently, the publica-
tion of the study by Davies et al. (2002)
reporting a high frequency of activating
BRAF mutations in melanoma attracted
much attention in the research commu-
nity. Indeed, many independent groups
have confirmed the high frequency of
BRAF mutations in patients with mela-
noma; the mutation data on the COS-
MIC website (http://www.sanger.ac.uk/
genetics/CGP/cosmic/) indicate that
BRAF mutations were detected in 46%
of melanoma patients (n¼3,634), with
BRAF V600E being the predominant
mutation, found in 37.2% of the ana-
lyzed patients. However, given that in
benign melanocytic nevi the frequency
of BRAF mutations is similarly high
(35% total mutations; 29.5% BRAF
V600E; n¼830, including 358 Spitz
and blue nevi having a BRAF mutation
frequency of B7%), BRAF mutations
alone are not sufficient to initiate
malignant melanoma. This thesis is
sustained by experimental data showing
that ectopic expression of constitutive
active BRAF leads to senescence
of primary cells (Michaloglou et al.,
2005). An autocrine/paracrine regu-
latory loop explaining this observation
was recently described by Wajapeyee
et al. (2008), who demonstrated the
presence in normal cells of a basal
expression of insulin-like growth factor–
binding protein 7 (IGFBP7) that inhibits
BRAF–MEK–ERK signaling and thereby
restrains apoptosis. In nevi, BRAF muta-
tions activating the MAP kinase path-
way lead to an increased expression of
IGFBP7, which not only inhibits BRAF–-
MEK–ERK signaling but also activates
senescence. In contrast, in BRAF-
mutated melanoma lesions, IGFBP7
expression is absent, enabling the cells
to escape from senescence and thereby
exhibit uncontrolled proliferation.
Besides delivering the explanation for
the observed effects of constitutive
BRAF activation, the article by Waja-
peyee and colleagues demonstrates a
potential therapeutic application of this
knowledge: treatment with recombinant
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Figure 1. IGFBP7 expression in melanoma lesions. Primary tumors (a) or metastases (b and c) were
stained with an anti-IGFBP7 antibody. Representative examples of lesions with BRAF mutations showing
IGFBP7 expression (a and b) and with wt BRAF characterized by low IGFBP7 expression (c). (d) The
results for all samples (34 wt and 23 BRAF-mutated lesions) are depicted. There is no significant
difference between the two groups (Mann–Whitney test; P¼0.1609). Bar¼100 mm.
Abbreviation: IGFBP7, insulin-like growth factor–binding protein 7
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IGFBP7 of BRAF-mutated melanoma
cells triggered their apoptosis both
in vitro and in vivo in a xenotrans-
plantation model. Similarly, reacti-
vation of IGFBP7 by DNA demethy-
lation inhibits colon cancer cell growth
in vitro (Lin et al., 2008). With this
therapeutic implication in mind, we
further scrutinized the expression of
IGFBP7 in melanoma. To this end, we
stained formalin-fixed tissues obtained
from 41 primary tumors and 16 metas-
tases for IGFBP7 expression. Unlike
Wajapeyee and colleagues, however,
we did not detect a clear demarcation
of IGFBP7 expression between BRAF wt
(wild type) and mutated melanoma
lesions (Figure 1). Indeed, although the
frequency of IGFBP7-expressing cells
is lower in BRAF-mutated melanoma
lesions overall, the whole diversity of
IGFBP7 expression from absent to
present in 100% of tumor cells was
observed in both wt and BRAF-mutated
lesions (P¼0.1609; Mann–Whitney
test). Accordingly, western blot analysis
of short- and long-term cultured
melanoma cell lines did not show any
correlation between IGFBP7 protein
expression and BRAF status either
(Figure 2). Heterogeneous IGFBP7 ex-
pression could still be in accordance
with the reported stringent IGFBP7/
BRAF correlation, assuming a corre-
sponding heterogeneity in the BRAF
status. However, the homogeneous
IGFBP7 expression in some of the
BRAF-mutated tumors, as well as the
lack of correlation for the cell lines,
with one of them being hemizygote for
the V600E BRAF mutation, argues
against an obligatory downregulation
of IGFBP7 expression in BRAF-mutated
melanoma cells. Rather, it seems that
loss of IGFBP7 expression is not the
only way to overcome MAPK
pathway–induced senescence. In this
regard, dysregulation of the other
16 candidates detected by Wajapeyee
et al. (2008), including BNIP3L, FOXA,
and NF2, may be alternative mediators
for overcoming senescence. Thus, de-
tailed studies scrutinizing different
modi operandi by which melanoma
cells overcome BRAF-induced senes-
cence are needed before the potential
of IGFBP7 substitution for treatment of
melanoma can be estimated.
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TO THE EDITOR
Dendritic cells (DCs) have crucial roles
in driving primary immune responses
toward immunity or tolerance. While
immature DCs prompt tolerance in
peripheral tissues, mature DCs drive
immunity in lymph nodes (Banchereau
et al., 2000). A particular subset
of DC, however, is thought to have
the ability to induce tolerance regard-
less of the maturation state (Gilliet and
Liu, 2002).
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Figure 2. Lack of correlation between NRAS/BRAF mutational status and IGFBP7 expression in
melanoma cell lines. The NRAS/BRAF status of cell lines was determined by sequencing. Lysates from
these short- and long-term cultured melanoma cell lines were subsequently evaluated using western blot
analysis for IGFBP7 expression.
Abbreviations: DC, dendritic cell; IDO, indoleamine 2,3-dioxygenase; pDC, plasmacytoid DC; SLN,
sentinel lymph node; TLR, toll-like receptor
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Tolerogenic pDC in Melanoma Sentinel Nodes
